THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA. The ...

Core Insights - Autonomix Medical, Inc. has presented new clinical data showing significant pain relief in pancreatic cancer patients across all disease stages, emphasizing the effectiveness of their nerve-targeted treatment approach [1][2][4]. Group 1: Clinical Findings - The post hoc subgroup analysis from the ongoing Proof-of-Concept study indicates consistent pain reduction in pancreatic cancer patients treated with a transvascular RF denervation platform, regardless of disease severity [2]. - Rapid onset of pain relief was observed, with patients showing marked reduction in average pain within 24 hours post-procedure [6]. - At 7 days post-procedure, 93.75% of responding patients improved from severe pain to mild or moderate pain, with some achieving near-elimination of pain [6]. - Sustained benefits were noted, with approximately two-thirds of responding patients maintaining mild or eliminated pain levels at 4-6 weeks post-procedure [6]. - At 3 months post-procedure, no responding patients reported severe pain, and 50% maintained mild or eliminated pain levels [6]. - Notably, even late-stage (Stage 4) cancer patients experienced meaningful pain relief, transitioning from severe to mild or moderate pain [6]. Group 2: Presentation Details - The findings were presented at the 2026 ASCO Gastrointestinal Cancers Symposium, under the poster titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" [4][5]. - The presentation was made by Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc., during Poster Session B [5]. Group 3: Company Overview - Autonomix Medical, Inc. focuses on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform system technology that includes a catheter-based microchip sensing array [6][8]. - The company is initially developing its technology for pain treatment, particularly targeting pancreatic cancer, which is known for causing debilitating pain and lacking reliable solutions [8].

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 100 points, down 0.22% to 48,353.51, NASDAQ slipping 0.16% to 23,436.70, and S&P 500 dropping 0.13% to 6,896.56 [1] - Energy shares rose by 0.6%, while consumer discretionary stocks fell by 0.3% [1] Commodity Prices - Oil prices increased by 0.5% to $58.34, gold rose by 0.9% to $4,383.10, silver surged 7.2% to $75.515, and copper climbed 2.6% to $5.7105 [5] European Market Performance - European shares showed positive movement, with the eurozone's STOXX 600 gaining 0.53%, Spain's IBEX 35 Index rising 0.85%, London's FTSE 100 up 0.70%, Germany's DAX 40 increasing by 0.57%, and France's CAC 40 rising 0.63% [6] Asian Market Performance - Asian markets closed mostly lower, with Japan's Nikkei 225 down 0.37%, Hong Kong's Hang Seng Index up 0.86%, China's Shanghai Composite slightly down by 0.004%, and India's BSE Sensex falling 0.02% [7] Company-Specific Movements - FONAR Corporation shares surged 28% to $18.82 following confirmation of a take-private deal [8] - Autonomix Medical, Inc. shares increased by 30% to $0.6943 after receiving a patent grant [8] - Cemtrex, Inc. shares rose 40% to $2.9500 as the company returned to profitability [8] - Flushing Financial Corporation shares dropped 8% to $15.46 amid a merger announcement and strategic investment [8] - New Era Energy & Digital, Inc. shares fell 23% to $2.07 following a lawsuit response [8] - OceanFirst Financial Corp. shares decreased by 6% to $18.42 after announcing an acquisition plan for Flushing [8] Economic Indicators - The Case-Shiller Home Price Index increased by 1.3% year-over-year in October, slightly down from a 1.4% increase in the previous month and above market estimates of 1.1% [10] - The FHFA house price index rose 0.4% in October, following a 0.1% decline in September, and compared to market estimates of a 0.1% increase [10] - The Chicago Business Barometer surged to 43.5 in December from 36.3 in the previous month, exceeding market expectations of 39.5 [10]

Core Insights - Autonomix Medical, Inc. has been granted a new European patent (EP4230133) that enhances its strategic position in the nerve-sensing and modulation market, which is valued in the multi-billion-dollar range [1][2] - The patent covers systems and methods for precise treatment of cardiac tissues, including feedback-driven neuromodulation and denervation, which could transform treatment in cardiology and related fields [1][2] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [4] - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, which could significantly improve patient outcomes [4] Technology and Applications - The newly granted patent expands the company's ability to provide precision nerve-targeted therapies for conditions such as hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - Autonomix's technology platform has the potential to address multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [3][5] Market Potential - The patent positions Autonomix to capitalize on high-growth areas in cardiology, potentially reducing complications associated with traditional systemic treatments [2] - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [5]

Core Insights - Autonomix Medical, Inc. is focused on advancing precision nerve-targeted treatments and has recently participated in a Virtual Investor CEO Connect segment [2][3] - The CEO, Brad Hauser, highlighted two main priorities: strengthening intellectual property protection and exploring applications beyond pancreatic cancer, including cardiovascular, pulmonary, and interventional pain management [3] Company Overview - Autonomix is a medical device company that aims to revolutionize the diagnosis and treatment of diseases involving the nervous system through innovative technologies [4] - The company's platform technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Technology and Applications - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5] - The platform is still investigational and has not yet received marketing clearance in the United States [5]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system [3] - The company's first-in-class platform system technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [3] Product Development - The initial focus of the technology is on pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Presentation - Autonomix announced that its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium [1] - The presentation will focus on a long-term analysis of pain mitigation in pancreatic adenocarcinoma through denervation via transvascular RF energy-based ablation [1] - The poster session is scheduled for January 9, 2026, with specific time slots for presentation [1]

Core Insights - Autonomix Medical, Inc. is focusing on advancing precision nerve-targeted treatments and has published a CEO Corner segment discussing its strategic direction [1] - The company aims to protect its platform's strength through intellectual property and is exploring new opportunities beyond pancreatic cancer into cardiovascular, pulmonary, and chronic pain areas [1] Company Overview - Autonomix is a medical device company dedicated to innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases across the body [3] Current Development Focus - The initial development of the technology is targeted at pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing multiple indications, including cardiology, hypertension, and chronic pain management [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. announced significant improvements in quality of life for patients with severe pancreatic cancer pain following a targeted ablation therapy, as evidenced by a post-hoc exploratory subgroup analysis of its proof-of-concept study [1][4][5] Study Findings - The analysis utilized the EORTC QLQ-C30 scale to assess quality of life, symptom burden, and functionality across various patient subgroups, including those with different tumor stages and metastatic statuses [1][4] - Late-stage patients demonstrated substantial improvements, indicating that the ablation therapy provided clinically meaningful changes even in advanced disease [1][4] - Average symptom scores improved by 14.53 points at 4–6 weeks and 26.07 points at 3 months, with functionality and global quality of life also showing significant enhancements [7][10] - Patients with Stage 4 pancreatic cancer experienced a 32.48 point improvement in symptoms and an 11.85 point functional gain by 4–6 weeks, with sustained benefits at 3 months [7][10] Clinical Trial Insights - The findings will inform the design and patient selection for Autonomix's upcoming U.S.-based multicenter clinical study, set to begin in 2026, which will formally evaluate pain relief and quality-of-life outcomes [2][6] - The initial proof-of-concept study enrolled 20 patients, with 100% of responding patients achieving opioid-free status at 3 months post-procedure [10][17] Future Directions - Based on the positive results from the proof-of-concept study, Autonomix is expanding its research to include additional visceral cancers and earlier-stage pancreatic cancers, aiming to address a broader market for interventional cancer pain management [11][12]

Core Insights - Autonomix Medical, Inc. will present at the TCT 2025 Annual Scientific Conference, showcasing its innovative nerve-targeted treatment technology [1][2] - The presentations will focus on the initial phase results of a clinical study aimed at alleviating pain in pancreatic cancer patients through transvascular energy delivery [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [4] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with high sensitivity [4][5] - Initial development efforts are concentrated on pain management, particularly for pancreatic cancer, which currently lacks effective treatment options [5] Conference Details - TCT 2025 is a four-day educational conference focused on interventional cardiovascular medicine, taking place from October 25-28, 2025, in San Francisco [3] - The conference is organized by the Cardiovascular Research Foundation and has grown significantly since its inception in 1988, now attracting thousands of attendees [3]

Core Insights - Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, showcasing its commitment to advancing precision nerve-targeted treatments [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Technology Development - Initial development of the technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]